Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1002/oby.70067 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment Xuan Li Dachuang Cao Helene Sapin Fangyu Wang Theresa Hunter Gibble Nedina Kalezic Raibulet Max Denning Lee M. Kaplan Obesity ABSTRACT Objective This post hoc analysis of SURMOUNT trials assessed the association of baseline physical function (PF) with obesity‐related complications (ORCs), efficacy measures, and PF. The mechanism of tirzepatide‐led improvements in PF was evaluated. Methods Outcomes were assessed among participants (SURMOUNT‐1 = 2539; SURMOUNT‐3 = 579; SURMOUNT‐4 = 670) grouped by baseline quartiles (Q) of SF‐36v2 PF scores within study (higher scores = better PF). Least‐squares mean changes from baseline in efficacy measures and PF were estimated using ANCOVA. Pearson's correlation between weight reduction and improvement in PF was calculated. Results In SURMOUNT‐1, participants with lower baseline PF had more ORCs. Tirzepatide‐treated participants showed similar reductions in weight (kg; −20.1% to −22.8%), waist circumference (−17.2 to −20.2 cm), and BMI (−7.2 to −9.0 kg/m 2 ) across quartiles. Participants with lower baseline PF reported greater improvements in PF with tirzepatide (Q1 = 12.5; Q4 = −0.8). Results were similar in SURMOUNT‐3 and SURMOUNT‐4. A weak to mild correlation was noted between weight reduction and improved PF; the strength of correlation decreased from Q1 to Q4. Conclusions Lower baseline PF was associated with a higher prevalence of ORCs. Patients taking tirzepatide experienced substantial weight loss, regardless of their baseline PF. Tirzepatide may improve PF through both weight loss‐dependent and ‐independent mechanisms, especially in those with lower baseline PF. Trial Registration ClinicalTrials.gov identifiers: SURMOUNT‐1, NCT04184622; SURMOUNT‐3, NCT04657016; SURMOUNT‐4, NCT04660643 10.1002/oby.70067 http://creativecommons.org/licenses/by/4.0/